Page 60 - Read Online

Kamal et al. J Transl Genet Genom 2024;8:162-85 https://dx.doi.org/10.20517/jtgg.2023.55 Page 184

Ocul Immunol Inflamm 1999;7:189-98. DOI PubMed
125. Parham JS, Goldberg AC. Mipomersen and its use in familial hypercholesterolemia. Expert Opin Pharmaco 2019;20:127-31. DOI
PubMed PMC
126. Scott LJ. Givosiran: first approval. Drugs 2020;80:335-9. DOI PubMed
127. Gebert LF, Rebhan MA, Crivelli SE, Denzler R, Stoffel M, Hall J. Miravirsen (SPC3649) can inhibit the biogenesis of miR-122.
Nucleic Acids Res 2014;42:609-21. DOI PubMed PMC
128. Gallant-Behm CL, Piper J, Lynch JM, et al. A MicroRNA-29 mimic (Remlarsen) represses extracellular matrix expression and
fibroplasia in the skin. J Invest Dermatol 2019;139:1073-81. DOI
129. Regulus Therapeutics I. RG-125 (AZD4076), a microRNA therapeutic targeting microRNA-103/107 for the treatment of NASH in
patients with type 2 diabetes/pre-diabetes, selected as clinical candidate by AstraZeneca. 2015. Available from: https://www.
prnewswire.com/news-releases/rg-125-azd4076-a-microrna-therapeutic-targeting-microrna-103107-for-the-treatment-of-nash-in-
patients-with-type-2-diabetespre-diabetes-selected-as-clinical-candidate-by-astrazeneca-300062261.html [Last accessed on 1 Apr
2024].
130. Bouchie A. First microRNA mimic enters clinic. Nat Biotechnol 2013;31:577. DOI
131. Siddiqui MA, Keating GM. Pegaptanib: in exudative age-related macular degeneration. Drugs 2005;65:1571-7; discussion 1578-9.
DOI PubMed
132. Goodkey K, Aslesh T, Maruyama R, Yokota T. Nusinersen in the treatment of spinal muscular atrophy. In: Yokota T, Maruyama R,
editors. Exon skipping and inclusion therapies. New York: Springer; 2018. pp. 69-76. DOI
133. Hoy SM. Patisiran: first global approval. Drugs 2018;78:1625-31. DOI PubMed
134. Scott LJ, Keam SJ. Lumasiran: first approval. Drugs 2021;81:277-82. DOI PubMed
135. Bravo-Hernandez M, Tadokoro T, Navarro MR, et al. Spinal subpial delivery of AAV9 enables widespread gene silencing and blocks
motoneuron degeneration in ALS. Nat Med 2020;26:118-30. DOI PubMed PMC
136. Arun G, Diermeier SD, Spector DL. Therapeutic targeting of long non-coding RNAs in cancer. Trends Mol Med 2018;24:257-77.
DOI PubMed PMC
137. Matsui M, Corey DR. Non-coding RNAs as drug targets. Nat Rev Drug Discov 2017;16:167-79. DOI PubMed PMC
138. Lennox KA, Behlke MA. Cellular localization of long non-coding RNAs affects silencing by RNAi more than by antisense
oligonucleotides. Nucleic Acids Res 2016;44:863-77. DOI PubMed PMC
139. Gagnon KT, Li L, Chu Y, Janowski BA, Corey DR. RNAi factors are present and active in human cell nuclei. Cell Rep 2014;6:211-
21. DOI PubMed PMC
140. Kumar H, Kawai T, Akira S. Pathogen recognition by the innate immune system. Int Rev Immunol 2011;30:16-34. DOI PubMed
141. Sioud M. Single-stranded small interfering RNA are more immunostimulatory than their double-stranded counterparts: a central role
for 2'-hydroxyl uridines in immune responses. Eur J Immunol 2006;36:1222-30. DOI PubMed
142. Barton GM, Medzhitov R. Toll-like receptor signaling pathways. Science 2003;300:1524-5. DOI PubMed
143. Hong DS, Kang YK, Borad M, et al. Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours.
Br J Cancer 2020;122:1630-7. DOI PubMed PMC
144. Beg MS, Brenner AJ, Sachdev J, et al. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients
with advanced solid tumors. Invest New Drugs 2017;35:180-8. DOI PubMed PMC
145. Pisano M, Baldinu P, Sini MC, Ascierto PA, Tanda F, Palmieri G. Targeting Bcl-2 protein in treatment of melanoma still requires
further clarifications. Ann Oncol 2008;19:2092-3. DOI PubMed PMC
146. Anderson EM, Miller P, Ilsley D, et al. Gene profiling study of G3139- and Bcl-2-targeting siRNAs identifies a unique G3139
molecular signature. Cancer Gene Ther 2006;13:406-14. DOI
147. Winkler J, Stessl M, Amartey J, Noe CR. Off-target effects related to the phosphorothioate modification of nucleic acids.
ChemMedChem 2010;5:1344-52. DOI
148. Wen J, Friedman JR. miR-122 regulates hepatic lipid metabolism and tumor suppression. J Clin Invest 2012;122:2773-6. DOI
PubMed PMC
149. Ui-Tei K, Naito Y, Nishi K, Juni A, Saigo K. Thermodynamic stability and Watson-Crick base pairing in the seed duplex are major
determinants of the efficiency of the siRNA-based off-target effect. Nucleic Acids Res 2008;36:7100-9. DOI PubMed PMC
150. Grimm D, Streetz KL, Jopling CL, et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways.
Nature 2006;441:537-41. DOI
151. Khan AA, Betel D, Miller ML, Sander C, Leslie CS, Marks DS. Transfection of small RNAs globally perturbs gene regulation by
endogenous microRNAs. Nat Biotechnol 2009;27:549-55. DOI PubMed PMC
152. Hart M, Nickl L, Walch-Rueckheim B, et al. Wrinkle in the plan: miR-34a-5p impacts chemokine signaling by modulating CXCL10/
+ +
CXCL11/CXCR3-axis in CD4 , CD8 T cells, and M1 macrophages. J Immunother Cancer 2020;8:e001617. DOI PubMed PMC
153. LaCasse EC. Pulling the plug on a cancer cell by eliminating XIAP with AEG35156. Cancer Lett 2013;332:215-24. DOI PubMed
154. Fazaeli H, Sheikholeslami A, Ghasemian F, Amini E, Sheykhhasan M. The emerging role of LncRNA FENDRR in multiple cancers:
a review. Curr Mol Med 2023;23:606-29. DOI PubMed
155. da Silva AMG, Cruz MS, de Souza KSC, Silbiger VN. Long non-coding RNA and circular RNA: new perspectives for
molecular pathophysiology of atrial fibrillation. Mol Biol Rep 2023;50:2835-45. DOI PubMed
156. Loganathan T, Doss C GP. Non-coding RNAs in human health and disease: potential function as biomarkers and therapeutic targets.